Summary of the Anglonordic Biotech Conference IV, 2007

On May 31, 2007, Ezenze, the Nordic Trade Councils, UK Trade & Investment and Atlas Venture organised the fourth Anglonordic Biotech Conference, which was held at the DTI’s Conference Centre in London.
The main aim of the conference was to promote and initiate partnerships, investment and alliances between the regions and provide information about the latest news on European biotech funding and strategic partnering. In total approximately 220 key decision makers from 180 biotechnology-, biopharmaceutical- and venture capital companies attended the one-day conference.

New to the conference 2007 was that is was divided up into four areas which had activities ongoing simultaneously. The four areas were the Main Conference Room, Atlas Venture’s Investment Room, the One-to-one meeting area and the Lounge & Exhibition area.
This year the conference had 104 pre-booked one-to-one meetings and assumable over 300 casual meetings were taking place in the lounge area.

A big success of the fourth conference was Atlas Venture’s Investment Room that offered 22 biotechnology companies the opportunity to do investment pitches in front of an audience of 45 European Investment firms and pharmaceuticals.

Gold sponsors



Silver Sponsors: Capio Diagnostic, Think London, Scottish Development International
Bronze Sponsors: Smerud Medical Research, Eden Biodesign
Supporting Sponsors: TVM Capital, Scandinavian Life Science Venture, Coulter Partners, Imro Tramarko, Halsin Partners
Media Partners: New Scientist, Nature, Bio World, Pharmabiz

Conference Programme 2007
Chairman of the conference: Tim Sparey, Director, Scientific Liaison Licensing and External Research, Europe , Merck Sharp & Dohme

09.00 – 09.30

Registration and coffee
09.30 – 09.40 Introduction by the Chairman of the Conference
09.40 – 09.50 Welcome on behalf of Mr Staffan Carlsson, Ambassador of Sweden
09.50 – 10.25

Partnering Pitches
       -  Photocure - Dr. Kjetil Hestdal, CEO
       -  Stricent - Jerker Ringström, CEO
       -  Ludesi - Ola Forsström-Olsson, CEO

10.25 – 10.50  Collaboration Strategy at Merck to Facilitate Drug Discovery and Development - Examples from Early and Late Stage Deals and Acquisitions - Hans Boström, Director, Scientific Liaison, Licensing and External Research, Europe, Merck Sharp & Dohme

10.50 – 12.10 

The Next Thing in Drug Discovery
Moderator: Melanie Senior,
European Editor & Director - Windhover Information               Participants:
       - Sweden – Protein Atlas – Prof. Stefan Ståhl
       - Denmark – Personalized Medicine – Prof. Steen-Sindet Pedersen
       - Norway – Population-based biobanks – Dr. Kristian Hveem
       - United Kingdom – Stem Cell research – Dr. Stephen Minger
Panel discussion

12.10 – 13.10 Lunch
13.10 – 13.45  Partnering Pitches
    
   -  Galapagos  - David Phillips, Senior Vice President
       -  Lytix Biopharma - Øystein Rekdal, CEO
       -  Cresset BioMolecular Discovery - Dr Sally Rose, Director
13.45 – 14.15  Top 10 tips from Bird & Bird on M&A and Corporate Transactions in the Life Science Sector - Matt Dennis, Partner, London & Sally Shorthose, Partner, London, Ulf Lundberg, Head of Life Science Sector Group, Stockholm, Bird & Bird
14.15 – 14.45  Early Phase Drug Development - Yvonne Lech, CEO, Capio Diagnostik and Knut T. Smerud, CEO, Smerud Medical Research International
14.45 – 15.15  Keeping Your Options Open: How European Biotechnology Companies Can Best Prepare for a Dual Exit Strategy – Dr Regina Hodits, Partner in the Life Science Sector, Atlas Venture LLP
15.15 – 15.45  Q&A and Conclusions
15.45 – 19.00   Buffet and Drinks


Summary of the Anglonordic Biotech Conference III - 2006

On May 4, 2006, Ezenze, the Nordic Trade Councils and UK Trade & Investment organised the third Anglonordic Biotech Conference, which was held at the DTI’s Conference Centre in London.

The main aim of the conference was to promote and initiate partnerships and alliances between the regions and provide information about the latest news on European biotech funding and strategic partnering. In total approximately 170 key decision makers from 130 British and Nordic biotech, pharmaceutical and venture capital companies attended the one-day conference. 85% of the delegates were at CEO, CFO, VP or Investment Manager Level. Conference benefits included an interactive website with possibilities of pre-arranging meetings. On this years conference there were 91 pre-booked one-to-one meetings and assumable over 300 casual meetings. The evaluation made after the conference showed that 97% of the attending companies have had further business contacts with the companies visiting the conference. This conference was covered by several magazines such as "Nature", "New Scientist" etc

Gold sponsors



Sponsors
Awex (Wallonia Region of Belgium)
Bavarian Nordic
Capio Diagnostik
Novo Nordisk
Trigen

Conference Programme 2006
Moderator
: Mr Perry Yam, Partner, SJ Berwin LLP, Corporate Finance Department
09.30 - 10.00 Registration and coffee
10.00 - 10.10 Conference Introduction – Mr Perry Yam, Partner, SJ Berwin LLP
10.10 – 10.20
Welcome on behalf of the Nordic Trade Councils and UK Trade & Investment -
Mr Tom Risdahl Jensen, Ambassador of Denmark
Dr Rob Morgan, Director, DTI Bioscience Unit
10.20 - 11.40 Elevator Pitches (4 company presentations)
- Affitech, Martin Welschof, CEO
- Bionor Immuno, Dr Birger Sørensen, CEO
- ENKAM Pharmaceuticals, Morten Albrechtsen, CEO
- Lyfjathroun hf, Thora Bjorg Magnusdottir, CEO
11.40 - 12.10
(Case Study) Successful International Pharmaceutical agreements – NicOx S.A's Ophthalmology Deal with Pfizer , presented by Damian Marron, Vice President Corporate Development, NicOx and Andrew Shindler, Partner, SJ Berwin LLP. Read the Case Study press release
12.10 - 13.30 Lunch
13.30 - 14.00 (Case Study) Successful M & A venture shares its experience from the M&A process – Dr. Sanjay Kakkar, CEO, Trigen Ltd
14.00 – 15.00 Elevator Pitches (3 company presentations)
- Neuronova, Johan Häggblad, Head of Business Development
- NsGene, Bo Karmark, Chief Financial Officer
- Tripep, Anders Vahlne, Head of Research
15.00– 15.30 Latest news from the Venture Capital Industry (US versus Europe) – Dr Nessan Bermingham, Principle of Life Sciences, Atlas Venture LLP
15.30 - 16.00 Q & A and panel discussions
16.00 - 19.00 Buffet and drinks

Press here for a printable version of the schedule

Elevator Pitches
Affitech - "Creating a therapeutic antibody pipeline through technology-based collaborations and partnerships", Martin Welschof, CEO
Bionor Immuno - "HIV immunotherapy - presentation of clinicial phase II data." , Dr Birger Sørensen, CEO
ENKAM Pharmaceuticals - "generating novel treatments for neurodegenerative disorders and cancer”, Morten Albrechtsen, CEO
Lyfjathroun hf - "Nasal drug delivery. Rapid systemic effect without the needle.", Þóra Björg Magnúsdóttir
Neuronova - "Therapeutic neurogenesis, new paradigm and treatment opportunity for neurology indications.", Johan Häggblad, Head Business Development
NsGene - "unique biodelivery technology to treat neurological disorders", Jens Viktor Nørgaard, Director of Intellectual Property Rights
Tripep - "New approaches for the treatment of HIV and hepatitis C virus infections", Anders Vahlne, Head of Research

Attending companies

3H Biomedical AB
3i
Abingworth
Activision Life International A/S
AcurePharma AB
AERES
Affitech AS
Alizyme
Amura
Antisoma
Atlas Venture
Avecia Ltd
Arrow Therapeutics Ltd
Astellas Pharma Europe
Awex
Axis-Shield plc
Bactus AB
Bavarian Nordic A/S
Bergen Techtrans Office AS
Bioanalab ltd
Biokapital Ltd
Biomedical Venture, BankInvest Group
Bionor Immuno
Biotec Pharmacon ASA
Biosergen AS
Birkeland Innovation AS
Cambridge Antibody Technology
Capio Diagnostik
CeNeS Pharmaceuticals plc
Center for Research on Pharmaceuticals
Chemilia
Curidium Limited
DiaGenic ASA
Domainex Ltd
DTI Global Watch Service
EiRx Therapeutics plc
ENKAM
Endocrine Pharmaceuticals Limited
Eurocine vaccines AB
Ezenze
Farallone Therapeutics BV
Forskningsstiftelsen
Giga
Glucox Biotech AB
Glycoform Ltd
HealthCap
Innovation Norwayz
Innovationskapital
Ionscope Ltd
Isis Innovation Ltd
ITX Corporation
Ixico Ltd
Kudos Pharmaceutical
Litis
London Stock Exchange
Ludesi
Lyfjathroun hf
Lytix Biopharma AS
Medinnova AS
MedPharm Ltd
MedTech Trondheim AS
Merck
Merlin Biosciences
MRC Technology (MRCT)
Nannovation Biotech Aps
NatImmune A/S
Naturejobs
NeuroNova
Nicox
Nova Thera Ltd
Novo Nordisk A/S
NsGene A/S
NTNU Technology Transfer AS
Olink Bioscience
Optinose AS
Orla Protein Technologies
Osteologix A/S
Oxford Immunotec Ltd
Oxigene, Inc
Paramount Biosciences
PharmaSurgics in Sweden AB
Pharmidex
PhotoCure ASA
Physiomics Plc
Phytopharma Plc
Pipeline Biotech A/S
Piramed
Proxima Concepts Ltd
Santosolve AS
Sareum Ltd
Sarsia Life Science Fund
Seymour Pierce Limited
Shire Pharmaceuticals Group Limited
SJ Berwin
SLP Innovations Ltd
Sophion Bioscience A/S
Stricent AB
Swedish Trade Council
SåkorninVest AS
The Embassy of Denmark in London
The Norwegian Radium Hospital Research Foundation
Therapeutic Antibody Centre
Thia Medica AS
Thiakis Ltd
TraceTag International Ltd
Trade Council of Denmark in the UK
Trade Council of Iceland
Trigen
Trillium Medical Ventures
Tripep AB
TTO Nord AS
UCB Celltech
UCL
UK Trade & Investment
Vipergen


Summary of the Anglo-Nordic Biotech Conference II - 2005

On April 21 2005, the Nordic Trade Councils and the London Stock Exchange organised a follow-up conference to the highly appreciated Anglonordic Biotech Conference I held 1 April 2004 at the DTI's Conference Centre in London. This conference was held at London Stock Exchanges selected premises in the centre of London.

The main aim of the conference was to promote and initiate partnerships and alliances between the regions and provide information about the latest news on European biotech funding and strategic partnering. In total approximately 150 key decision makers from 100 British and Nordic biotech, pharmaceutical and venture capital companies attended the one-day conference. Conference benefits included an interactive website with possibilities of pre-arranging meetings. In total approximately 50 partner meetings were carried out during the conference day.

Gold sponsors



Sponsors
Novo Nordisk
Biofund
Invest in Finland
One NorthEast
Scottish Development International
UK Trade & Investment

Conference Programme 2005
10.30 - 11.10 Registration and coffee
11.10 - 11.20 Conference introduction – Dr Renny Leach, CEO BioKapital Ltd
11.20– 11.30
Welcome on behalf of the Nordic Trade Councils H.E. Mr Tarald O. Brautaset, Norwegian
Ambassador to the Court of St James's
11.30 - 12.00 Latest News on European Funding –
Dr Nessan Bermingham, Principal in the Life Sciences Sector, Atlas Venture
12.00 - 12.30
Negotiating Your Way into Big Pharma –
Dr Ray Hill, Executive Director, Licensing and External Research, Europe, Merck Sharp & Dohme
12.30 - 13.30 Lunch
13.30 - 14.00 Legal Issues to consider in Licensing Agreements – Mr Andrew Shindler, Partner, SJ Berwin
14.00– 14.30 Preparing for a Successful IPO –
Ms Anne Moulier, Corporate Account Management - International, London Stock Exchange
14.30– 15.00 Success story - How to make a strategic partnership with a government organisation –
Peter Wulff, CEO, Bavarian Nordic
15.00 - 16.00 Panel discussion - How can you make your company more attractive to investors and strategic partners?
Chair person: Perry Yam, Partner, SJ Berwin
Panel: Mr Viggo Birch, Managing Director & Vice President Europe, Novo Nordisk, Mr Peter Wulff,
CEO, Bavarian Nordic, Mrs Anki Forsberg, Partner, HealthCap Venture Capital, Mr Andrew Fraser, Director Healthcare, 3i plc
16.00 – 18.00 Buffet and drinks

Attending companies
(Click on 3i to see an example of how each attending company will be presented on the website).

3i
4bio AS
Abingworth
Acasiatrade
ACE BioSciences
Action Pharma
Advent Ventures
Aeres Biomedical
Affitech
Algeta ASA
Alizyme Therapeutics
Amura
Antisoma Plc
Applied Photophysics
Arrow Therapeutics
Astellas Pharma
Atlas Venture
Attana AB
Auvation
Avecia
Bavarian Nordic
Beocarta
Bio World
BioCule
Biofocus Plc
Biofund
BioKapital
Bionor Immuno AS
BioVenture View
Business Wire
Cambridge Enterprise
Capman Life Science
Celltech Group Plc
CeNes Pharmaceutical
Cronos Therapeutics
Dagens Industri
Danish Trade Council
Dansk Erhvervsinvestering
D-Gen Ltd
Egalet Etna
Enkam Pharmaceuticals
ExpressOn
BioSystems Ltd
Ferring Pharmaceuticals
Finpro
Gastrotech Pharma
GlaxoSmithKline
Global Life Science Venture
Hannah InterActions Ltd
Haptogen
HealthCap
Icelandic Heart Association
Immunobiology
In vivo, Europe
Innovation Norway
Integrin Advanced Biosyst.
Invest in Finland
In Vivo
Invivo Communications
Ionix Pharmaceuticals
Isis Innovation
Juvantia Pharma Oy
Karocell Karyon Oy
Kauppalehti
Lipoxen
London Stock Exchange
Lorantis
Ludesi
LUX Biotech
Lyfjathroun hf
Medivir
Medpharm Ltd
Merck Sharp & Dohme
Merlin Biosciences
Nature New Business Venture Fund
Newham University Hospital NHS Trust
New Scientist
Nova Thera
Novel Diagnostics
Novo Nordisk
NsGene A/S
One NorthEast
Onyvax
Optinose
Orf Liftaekni ehf
Orla Protein Technologies
OstomyCure AS
Paul Capital Partners
Pfizer
PrediChem
Prokaria
Proteome Sciences
Plcf Santaris
Pharma Scancell Limited
Scottish Biomedical
Scottish Development Int
Shire Pharmaceutical
SJ Berwin
Skandinavian Life Science Venture
Swedish Trade Council
Swedish BioScience Prog
Såkorn Invest
Trade Council of Iceland
Tripep
UK Trade & Investment
Unicrop
University College London

Summary of the Anglo-Nordic Biotech Conference I - 2004

On April 1 2004, the Nordic Trade Councils together with the UK Trade & Investment organised the first follow-up conference to the highly appreciated Anglo-Swedish Biotech Conference II in April 2003 at the London Stock Exchange in London. The Conference was held at DTI's selected Conference Centre on 1 Victoria Street.

In total approximately 160 key decision makers from 100 British and Nordic drug discovery, pharmaceutical and venture capital companies attended the one-day conference.

The main aim of the conference was to promote and initiate partnership and alliances between the regions, provide information about the latest news on European funding and to develop a forum that will make the European biotech market even more competitive.

Conference benefits included an interactive website with possibilities of pre-arranging meetings.

Gold sponsor
Silver Sponsors
New Scientist
UK Trade & Investment
Sponsors
Novo Nordisk
Biofund
Embassy of Sweden
Finn-Medi Research
Iceland Air

Invest in Finland
I Invest in Sweden Agency
Invest in Denmark
Maersk Air

Conference Programme 2004
10.30 - 11.00 Registration and coffee
11.00 - 11.15 Conference introduction – Dr Gareth W. Roberts, Director, Sciona
11.15 – 11.30
Opening remarks - H.E. Dr Mats Bergquist, Ambassador of Sweden welcomes Lord Sainsbury of Turville, Minister of Science & Innovation
11.30 - 12.00 Europe: Turning the Corner? – Mr Rod Perry, Director of Technology, 3i Group plc
12.00 - 12.45
Panel discussions – How Can You Make Your Company More Attractive to Investors?
Chairperson: Dr Gareth W. Roberts, Director, Sciona Panel: Mr Rod Perry, Director of Technology, 3i, Mr. Seppo Mäkinen, President, Senior Partner, Biofund, Mr Perry Yam, Partner, SJ Berwin, Mr Torbjörn Bjerke, CEO, Biolipox AB, Mr Flemming Pedersen, Executive Vice President, NeuroSearch A/S
13.00 - 14.30 Lunch
14.30 - 15.00 The Importance of Foreign Direct Investment and Global Partnerships – Mr Paul Whiteway,
Director, International, UK Trade & Investment
15.00 – 15.30 Biotechnology in the European Research Area -
Dr. Etienne Magnien, Research Directorate General, European Commission
15.30 – 16.00 Coffee
16.00 - 17.00 Panel discussions – How Can the Anglo-Nordic Region Cooperate in Order to Create a More Competitive European Biotech Market?
Chairperson: Dr Alison George, New Scientist.
Panel: Dr. Etienne Magnien, (see above), Mr. Lars Adlersson, CEO Medivir, CEO Novo Nordisk, Dr. Göran Ando, CEO Celltech Group, Dr. Esa Heinonen, Vice President for R&D, Orion
17.00 – 19.00 Networking – Buffet and drinks